Both medications follow predictable patterns, but the experience differs significantly between the two
Contraindications: Active uveal inflammation Most cases of angle-closure glaucoma , due to the possibility of increasing angle block Hypersensitivity to the active or inactive ingredients Side Effects: Retinal detachment has been reported in a few cases Stinging, burning, lacrimation Iris cysts may form Lens opacities Cardiac irregularities Pharmacokinetics: Administered in eye drops to patients with glaucoma ) Forms an irreversible covalent bond with the ACh binding site on cholinesterase (duration of action is ~100 hrs Drug Interactions: Potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects References: Merck Manual Professional Edition (2026): Medications Used to Treat Glaucoma

For Wegovy , NICEs semaglutide guidance is referenced in the tirzepatide appraisal as applying to adults with obesity within specialist weight management services, alongside diet and exercise, and for up to 2 years in that setting
The semaglutide versus tirzepatide comparison can help you evaluate which medication better fits your needs, including practical considerations like shipping and storage
Clinical trials have shown that semaglutide may raise resting heart rate by a few beats per minute, and in sensitive individuals, that change could lead to noticeable palpitations or irregular rhythms